Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers’ research partner secures grant

Ellex Medical Lasers’ research partner secures grant

Ellex Medical Lasers’ (ASX:ELX) research collaborator Professor Erica Fletcher from the University of Melbourne has been awarded a $355,000 Australian Research Council (ARC) Linkage grant.

The funds will be used to detail the precise effects its 2RT laser has on cells, cell populations and the body as a whole.

It will provide fundamental knowledge on the impact of 2RT™on cell biology of immune cells and cell signalling pathways in the retina.

The work will also give Ellex’s researchers a better understanding of the mechanism of action and potential uses of the 2RT laser currently in use in clinical trials for the treatment of early-stage age-related macular degeneration.

During FY2015, sales of commercial 2RT units increased to early adopters and research collaborators in Holland, Germany, Italy, France, New Zealand and Australia.

As of 15th June 2015, these commercial 2RT units had been used to perform approximately 1,500 procedures on 940 patients. These patients and treatments are in addition to the patients being treated in the LEAD trial.

The potential market for AMS across the U.S., UK, Germany, France, Spain, Italy and Japan will almost double in value to $10.1 billion by 2023 from $5.1 billion in 2013.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

November 30 2016

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use